



# PSILOCYBIN & MDMA



[3-(2-Dimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate  
C12H17N2O4P



3,4-Methylenedioxyamphetamine  
C11H15NO2

**MDMA**, because of its uncanny ability to foster feelings of security and well-being combined with acute focus, creates an ideal state for exploring traumatic events in the past. When the overarching feeling is 'safety', the mind is comfortable to explore, reprogram and heal trauma that may be quarantined in the deep recesses of the brain.

**Psilocybin** diverts cognitive priority from fear and survival based mechanisms to more conscious thought patterns, facilitating new ways to look at problems and reprogram mental disease. It can be an incredibly spiritual experience, often offering a different perspective on death and the nature of life itself.

## CANDIDATES

### 1 IN 5 MOOD DISORDERS

One in five of us will develop a mood disorder. By 2020, depression will rank second in morbidity among all illnesses worldwide.<sup>2</sup> Tragically, suicide, often triggered by a mood disorder, takes roughly a million lives worldwide every year.<sup>3</sup>

### 40 MILLION ADDICTION

Addiction is America's most neglected disease. According to a Columbia University study, "40 million Americans age 12 and over meet the clinical criteria for addiction involving nicotine, alcohol or other drugs." That's more Americans than those with heart disease, diabetes or cancer.<sup>4</sup>




**500,000 VETERANS AND FIRST RESPONDERS**

who served in Iraq or Afghanistan suffer from PTSD.<sup>1</sup>



**8.3 MILLION PSYCHOLOGICAL DISTRESS**

About 3.4 percent of the U.S. adult population, suffer from serious psychological distress, defined as a mental health problem severe enough to require treatment.<sup>5</sup>



**70% OF U.S. ADULTS TRAUMATIC EVENT**

at least once in their lives. This equates to approximately

**223.4 MILLION PEOPLE**<sup>6</sup>

## TRIAL RESULTS

### PSILOCYBIN-ASSISTED PSYCHOTHERAPY

### MDMA-ASSISTED PSYCHOTHERAPY

#### 1 SINGLE DOSE CURED<sup>7,8</sup>

Flexible dose of .3-4 mg per kg




**OF DEPRESSION AND ANXIETY IN THE PATIENTS STUDIED**

n=80

#### 3 SESSIONS CURED PTSD<sup>9</sup>

Flexible dose of 75-187.5 mg



**AND CONTINUED TO REDUCE IT FOR YEARS LATER**

n=107

#### PSILOCYBIN-FACILITATED SMOKING CESSATION<sup>10</sup>

Flexible dose of .29mg-.43mg per kg



At six months, **80%** of the participants were still abstinent.

n=15

#### SURVEYED 100 AUTISTIC ADULTS WHO HAD EXPERIENCED MDMA<sup>11</sup>



**72%** of MDMA experienced individuals reported being "more comfortable in social settings".

**12%** indicated that these effects lasted for **TWO OR MORE YEARS**

n=150

## ECONOMIC IMPACT



**ANXIETY DISORDERS ALONE HAVE AN ANNUAL COST OF \$42.3 BILLION<sup>6</sup> PTSD IS THE MOST COSTLY**

By enabling veterans to get off disability and return to work, this treatment could reduce the need for VA services, improve wait times, and reduce reliance on Social Security.

## WHAT DOES IT FEEL LIKE?

### THE SUBJECTIVE EFFECTS OF PSILOCYBIN

Psilocybin is a molecule that activates a particular type of serotonin receptor in the brain, and diverts cognitive priority to areas associated with higher thought processes.

- New perspective on emotional experiences
- Increased introspection
- Synaesthesia (mixing sensory modalities)
- Altered sense of time
- Heightened feelings of connectedness

### THE SUBJECTIVE EFFECTS OF MDMA

MDMA affects the brain by increasing activity levels of oxytocin, prolactin, dopamine, norepinephrine (noradrenaline), and serotonin.

- Increased empathy and compassion
- Enhanced communication and introspection
- Reduced feelings of fear
- Increased feelings of well-being
- Increased interpersonal trust
- Alert state of consciousness

### SUPPORTING PSYCHEDELIC MEDICINE IS SUPPORTING FULL LEGALIZATION

All of the current clinical trials are testing psychedelic medicine in controlled settings, with skilled practitioners present. Should psilocybin or MDMA become legal for medicinal use it will remain under these controlled conditions.

## MYTHS

#### SHROOMS ARE POISONOUS

It's important to differentiate mushroom poisoning from non-hallucinogenic species and "non-hallucinogenic" with hallucinogenic species. The active ingredient in 'Magic Mushrooms', psilocybin, has been shown to be safe for human consumption in clinical research.

#### SHROOMS MAKE YOU GO INSANE

There is no conclusive evidence suggesting that ingestion of psilocybin increases prevalence of mental health problems. However people with pre-existing conditions should refrain from recreational psychedelic use in the absence of a skilled medical practitioner.

#### MDMA IS THE SAME AS "ECSTASY" OR "MOLLY."

Substances sold on the street under these names may contain MDMA, but frequently also contain unknown and/or dangerous adulterants. These adulterants and substitute chemicals can be dangerous and as such, recreational use of "MDMA" contains inherent risk.

#### MDMA EATS AWAY AT YOUR BRAIN

There is no clinical evidence that moderate use of MDMA can cause damage to your brain. Frequent, high dose use can cause heart problems and memory problems. Early studies to the contrary have subsequently been retracted, as MDMA was accidentally mislabeled as the amphetamine tested.

1. M. Thompson, "Unlocking the secrets of PTSD," Time, vol. 185, no. 12, pp. 40-3, Apr. 2015.  
 2. Stanford Mood Disorders Center, "Pioneering Solutions for Depression and Bipolar Disorder," 2017. [Online]. Available: <http://med.stanford.edu/mooddisorders.html>.  
 3. World Health Organization, "Suicide Data," 2017. [Online]. Available: [http://www.who.int/mental\\_health/prevention/suicide/suicide-prevent/en/](http://www.who.int/mental_health/prevention/suicide/suicide-prevent/en/).  
 4. National Center on Addiction and Substance Abuse at Columbia University, "Addiction: A Preventable and Treatable Disease," New York, New York, USA, 2013.  
 5. J. Weissman, D. Russell, M. Jay, J. M. Beasley, D. Malaspina, and C. Pegasus, "Disparities in Health Care Utilization and Functional Limitations Among Adults With Serious Psychological Distress, 2006-2014," Psychiatr. Serv., p. appi.ps.2016002, 2017.  
 6. PTSD United, "PTSD Statistics," 2013. [Online]. Available: <http://www.ptsdunited.org/ptsd-statistics-2/>.  
 7. R. R. Griffiths et al., "Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial," J. Psychopharmacol., vol. 30, no. 12, pp. 1181-1197, Dec. 2016.  
 8. S. Ross et al., "Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial," J. Psychopharmacol., vol. 30, no. 12, pp. 1165-1180, Dec. 2016.  
 9. B. Burge, "PRESS RELEASE: FDA Grants Breakthrough Therapy Designation for MDMA-Assisted Psychotherapy for PTSD, Agrees on Special Protocol Assessment for Phase 3 Trials," Maps, 2017. [Online]. Available: <http://www.maps.org/news/media/6786-press-release-fda-grants-breakthrough-therapy-designation-for-mdma-assisted-psychotherapy-for-ptsd-agrees-on-special-protocol-assessment-for-phase-3-trials>.  
 10. M. W. Johnson, A. Garcia-Romeu, M. P. Cosimano, and R. R. Griffiths, "Pilot study of the 5-HT 2A agonist psilocybin in the treatment of tobacco addiction," J. Psychopharmacol., vol. 28, no. 11, pp. 983-992, Nov. 2014.  
 11. A. Danforth, "Courage, Connection, And Clarity: A Mixed-Methods Collective-Case Study Of Mdma (Ecstasy) Experiences Of Autistic Adults," Sofia University, 2013.